高级检索
当前位置: 首页 > 详情页

Construction of a 5 immune-related lncRNA-based prognostic model of NSCLC via bioinformatics

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 预警期刊

机构: [1]Department of Medical Oncology, The Fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China, [2]Undergraduate of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
出处:
ISSN:

关键词: Kyoto Encyclopedia of Genes and Genomes long noncoding RNA nonsmall cell lung cancer prognostic model the cancer genome atlas

摘要:
Participate in tumorigenic, oncogenic, and tumor suppressive pathways through gene expression regulation. We aimed to build an immune-related long noncoding RNA (lncRNA) prognostic model to enhance nonsmall cell lung cancer (NSCLC) prognostic prediction. The original data were collected from the cancer genome atlas database. Perl and R software were used for statistical analysis. The effects of lncRNAs expression on prognosis were analyzed by Gene Expression Profiling Interactive Analysis. Silico functional analysis were performed by DAVID Bioinformatics Resources. The median risk score as a dividing value separated patients into high- and low-risk groups. These 2 groups had different 5-year survival rates, median survival times, and immune statuses. The 5-lncRNA signature was validated as an independent prognostic factor with high accuracy (area under the receiver operating characteristic = 0.722). Silico functional analysis connected the lncRNAs with immune-related biological processes and pathways in carcinogenesis. The novel immune-related lncRNA prognostic model had significant clinical implication for enhancing lung adenocarcinoma outcome prediction and guiding the choice of treatment.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2021]版:
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Department of Medical Oncology, The Fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China, [*1]Department of Medical Oncology, The Fourth hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
通讯作者:
通讯机构: [1]Department of Medical Oncology, The Fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China, [*1]Department of Medical Oncology, The Fourth hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39767 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号